Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world outcomes of plasmablastic lymphoma: Treatment approaches and survival outcomes in the PLASMABLAT-001 cohort.

Leukemia research·2026
Same author

Plasmablastic Lymphoma: 2026 Update on Diagnosis, Risk Stratification, and Management.

American journal of hematology·2026
Same author

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

The Lancet. Haematology·2026
Same author

Hypoalbuminemia in MGUS: interpreting a prognostic signal within its biological context.

Blood cancer journal·2026
Same author

Zanubrutinib and pirtobrutinib show synergistic killing and suppression of BTK signaling in MYD88-mutated lymphoma cells.

Blood advances·2026
Same author

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.

Blood cancer journal·2026
Same journal

Dynamic Hemoglobin Trajectories in Renal Anemia and Their Association with Frailty Progression and Cardiovascular Events in Non-Dialysis Chronic Kidney Disease.

Mediterranean journal of hematology and infectious diseases·2026
Same journal

Early Predictive Value of Peripheral Inflammatory Index Combined with High-Sensitivity Troponin T for Sepsis-Induced Cardiomyopathy.

Mediterranean journal of hematology and infectious diseases·2026
Same journal

A Descriptive Preanalytical Survey of Procedures Followed for the Screening of Glucose Dysregulation in Thalassemia Centers: Implications for Clinical Practice and Call for Harmonization.

Mediterranean journal of hematology and infectious diseases·2026
Same journal

Atypical Evolution of a Vaso-Occlusive Presentation in Sickle Cell Disease: Lessons in Diagnostic Vigilance.

Mediterranean journal of hematology and infectious diseases·2026
Same journal

Mapping Three Decades of Research on Southeast Asian Ovalocytosis: A Bibliometric Analysis.

Mediterranean journal of hematology and infectious diseases·2026
Same journal

Omental Splenosis Mimicking Peritoneal Carcinomatosis.

Mediterranean journal of hematology and infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Apr 20, 2026

Assessing the Innate Sensing of HIV-1 Infected CD4+ T Cells by Plasmacytoid Dendritic Cells Using an Ex vivo Co-culture System.
08:11

Assessing the Innate Sensing of HIV-1 Infected CD4+ T Cells by Plasmacytoid Dendritic Cells Using an Ex vivo Co-culture System.

Published on: September 1, 2015

9.3K

Current knowledge on HIV-associated Plasmablastic Lymphoma.

Michele Bibas1, Jorge J Castillo2

  • 1Clinical Department, Hematology, National Institute for Infectious Diseases "Lazzaro Spallanzani" Rome, Italy.

Mediterranean Journal of Hematology and Infectious Diseases
|November 20, 2014
PubMed
Summary
This summary is machine-generated.

HIV-associated primary effusion lymphoma (PBL) is an aggressive AIDS-defining cancer. Diagnosis requires biopsy, and treatment involves chemotherapy, with specialized centers recommended for management.

More Related Videos

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

22.9K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

1.0K

Related Experiment Videos

Last Updated: Apr 20, 2026

Assessing the Innate Sensing of HIV-1 Infected CD4+ T Cells by Plasmacytoid Dendritic Cells Using an Ex vivo Co-culture System.
08:11

Assessing the Innate Sensing of HIV-1 Infected CD4+ T Cells by Plasmacytoid Dendritic Cells Using an Ex vivo Co-culture System.

Published on: September 1, 2015

9.3K
Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

22.9K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

1.0K

Area of Science:

  • Oncology
  • Hematology
  • Infectious Diseases

Background:

  • HIV-associated primary effusion lymphoma (PBL) is a distinct, aggressive AIDS-defining non-Hodgkin lymphoma.
  • Pathogenesis involves immunodeficiency, chronic immune stimulation, and Epstein-Barr virus (EBV) infection.
  • This rare cancer, with fewer than 250 published cases, predominantly affects the oral cavity but can occur in extraoral sites.

Purpose of the Study:

  • To summarize the clinical presentation, diagnosis, and management of HIV-associated PBL.
  • To highlight treatment strategies, prognostic factors, and outcomes for this rare lymphoma subtype.
  • To emphasize the need for specialized centers in managing HIV-positive PBL patients.

Main Methods:

  • Review of published literature on HIV-associated PBL.
  • Analysis of diagnostic criteria, including immunophenotyping (CD45, CD20, CD79a negative; CD38, CD138, MUM1 positive; EBER and KI67 >80%).
  • Evaluation of therapeutic approaches (CHOP, CODOX-M/IVAC, DA-EPOCH, cART, CNS prophylaxis, ABMT) and prognostic factors (remission, PS, stage, MYC, IPI).

Main Results:

  • Median progression-free survival (PFS) ranges from 6-7 months, and median overall survival (OS) ranges from 11-13 months.
  • Long-term survival is more frequently observed in pediatric patients.
  • Rituximab is ineffective due to CD20 negativity; CNS prophylaxis is mandatory.

Conclusions:

  • HIV-associated PBL is an aggressive lymphoma requiring prompt diagnosis and management.
  • Treatment strategies should be tailored, considering patient fitness and disease status.
  • Due to disease rarity and complexity, specialized centers are crucial for optimal patient care and research.